Report me for selling fake medicine? Why are you crying when your illness relapses?

"And I don't think this new drug is worth only 100 billion!"

Chen Xuan sneered in his heart. Qin Guoming's plan was indeed a good one.

Now he wants to acquire the new drug formula for just 100 billion yuan, and even thinks he is very generous.

The previous liver cancer medicine sold 50 billion in the overseas market alone, plus the 30% profit in the domestic market, that’s a price of 100 billion.

Does he think that the market for lung cancer-specific drugs will be smaller than that for liver cancer-specific drugs?

What's more, he had no fame before, which made his medicine less credible. In this case, the price was naturally low.

But now he has already become famous and has a very high reputation in the entire medical community.

This added fame alone has caused the value of the drug formula to skyrocket, making it impossible to maintain the original price.

"I understand, and I also know what Mr. Chen thinks."

"Mr. Chen believes that new drugs have greater market potential and their value should increase. This is very reasonable, and I agree with him."

Qin Guoming nodded in agreement with Chen Xuan's words, then changed the subject.

"But Mr. Chen may not have considered that your liver cancer drug has been tested on patients. It's mature, reliable, and safe, so its value is naturally higher."

"But your lung cancer drug is different. It's just been put into clinical trials, so whether it's effective or safe is still a different story. The risks are still very high, so you can't just treat it like a mature formula and evaluate its value."

Chen Xuan could accept his words.

The specific drug for lung cancer has indeed just begun clinical trials, no matter how perfect the previous tests were.

However, problems may still occur in clinical trials, leading to the complete failure of the drug trial.

Although the probability of this risk is very small, it does not mean that it will not happen, and this will indeed lead to the value assessment of the drug.

Qin Guoming is not talking nonsense. There is indeed a basis for this. The value of a drug will indeed be very different if it has passed clinical trials or not.

The success rate of a drug from phase I clinical trials to approval for marketing is approximately 12.38 percent. If we exclude oncology drugs, the success rate is 20.6 percent!

According to incomplete statistics, there have been nearly 700 verification clinical trials in the past ten years. From the first phase of clinical trials to approval, the overall success rate in the oncology field is only 5.2%.

The specific drug for lung cancer is obviously an anti-tumor drug, and it is an extremely rare specific drug. Its success rate should be the lowest among all drugs.

However, judging from the series of experimental data released by Chen Xuan, the success rate of lung cancer-specific drugs passing clinical trials and being approved for marketing will definitely not be lower than 90%.

The clinical trials of some drugs are actually a matter of luck, and the pharmaceutical companies themselves are not sure about the results.

Failure is acceptable, but success can bring huge profits, which is why pharmaceutical companies will advance clinical trials.

However, for some drugs, pharmaceutical companies themselves are already very confident in their clinical trials and believe that the success rate is very high, which makes them more willing to invest more resources.

……

……

The specific drug for lung cancer obviously has a very high success rate.

The chances of this drug failing are not negligible, but they are certainly very small.

Not only Chen Xuan, but also people outside believed that the clinical trial of this drug would definitely be successful.

Therefore, it is unnecessary for Qin Guoming to use this point to lower the value of the lung cancer drug.

The clinical trials have not been completed yet, so the valuation will indeed be lower, but not to such an exaggerated degree.

In particular, lung cancer specific drugs are currently irreplaceable anti-cancer drugs, and will be a monopoly in the market for a long time in the future.